Trial reportBritish journal of haematology2019
Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group.
Trial report in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Trial
- Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Trial
- Predictive and prognostic role of volumetric analyses and lymphoma dissemination in pediatric HL: a prospective, multicenter, cohort study.European journal of nuclear medicine and molecular imaging · 2026Trial
- Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.The New England journal of medicine · 2024Trial
- Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.JAMA network open · 2024Trial
- Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.The New England journal of medicine · 2022Trial
- Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group.International journal of radiation oncology, biology, physics · 2022Trial
- Trial
- Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.The Lancet. Haematology · 2022Trial
- Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Patterns of presentation and outcomes in stage IV Hodgkin lymphoma: A report from the Children's Oncology Group (COG) AHOD1331 trial.British journal of haematology · 2026Article
- Disordered differentiation and cellular senescence in pediatric Hodgkin Reed-Sternberg cells.Blood advances · 2026Article
- Prognostic utility of interimAsia Oceania journal of nuclear medicine & biology · 2026Article
- A phase I/II study of brentuximab vedotin + AVD in paediatric patients with advanced Hodgkin lymphoma.British journal of haematology · 2025Article
- Outcome and Challenges in the Treatment of Pediatric Hodgkin Lymphoma With Euronet-PHL-C1 Protocol: Experience From a Resource-Limited Country.Cancer medicine · 2025Article
- Automatic Quantification of Serial PET/CT Images for Pediatric Hodgkin Lymphoma Using a Longitudinally Aware Segmentation Network.Radiology. Artificial intelligence · 2025Article
- Body Composition at Diagnosis and Early Response in Pediatric Hodgkin Lymphoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Article
- Response-Based Approach for Pediatric Hodgkin Lymphoma in Nations with Restricted Resources.International journal of hematology-oncology and stem cell research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The AHOD0831 study for paediatric patients with high risk Hodgkin lymphoma tested a response-based approach designed to limit cumulative alkylator exposure and reduce radiation volumes. Patients (Stage IIIB/IVB) received two cycles of ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide). Rapid early responders [RER, no positron emission tomography (PET) activity above mediastinal blood pool] were consolidated with 2 cycles of ABVE-PC. Slow early responders (SER) received 2 cycles of ifosfamide/vinorelbine and 2 cycles of ABVE-PC. Radiotherapy was administered to sites of initial bulk and/or SER. By intent-to-treat analysis, 4-year second event-free survival (EFS; freedom from second relapse or malignancy) was 91·9% [95% confidence interval (CI): 86·1-95·3%], below the projected baseline of 95% (P = 0·038). Five-year first EFS and overall survival (OS) rates are 79·1% (95% CI: 71·5-84·8%) and 95% (95% CI: 88·8-97·8%). Eight of 11 SER patients with persistent PET positive lesions at the end of chemotherapy had clinical evidence of active disease (3 biopsy-proven, 5 with progressive disease or later relapses). Although this response-directed approach did not reach the ambitiously high pre-specified target for second EFS, EFS and OS rates are comparable with results of recent trials despite the reduction in radiotherapy volumes from historical involved fields. Persistent PET at end of chemotherapy identifies a cohort at an especially high risk for relapse/early progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.